Business
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline® and accelerated sales growth of the rest of the portfolio: total sales growth of around 10.0%2 at CER (prior guidance greater than 7.0%); core operating margin of around 35.0% of total sales (prior guidance grea
About this update from Ipsen Sa
[{"type":"image","alt":"Ipsen Pharma","displaySize":"","headline":null,"caption":"Ipsen Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/89RavcsKEHEdDt270X336Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline®","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline® and accelerated sales growth of the rest of the portfolio: total sales growth of around 10.0%2 at CER (prior guidance greater than 7.0%); core operating margin of around 35.0% of total sales (prior guidance greater than 32.0%)","length":335,"tagName":"p"}]},{"val":[{"type":"text","content":"Announcement today of the proposed acquisition of ImCheck Therapeutics bringing a first-in-class Phase II asset, expanding pipeline in oncology","length":143,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":657,"olType":false},{"type":"text","content":"PARIS, FRANCE, 22 October 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025.","length":205,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:103.54px;vertical-align:top;","val":[{"type":"text","content":"","length":6,"tagName":"p","attribs":{}}]},{"style":"width:68.47px;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"YTD 2025","length":8,"tagName":"p","attribs":{}}]},{"style":"width:68.4px;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"YTD 2024","length":8,"tagName":"p","attribs":{}}]},{"colspan":"2","style":"width:127.54px;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"% change","length":8,"ta...